For instance, G2019S and other mutations in the LRRK2 gene have been shown to increase kinase activity, and LRRK2 kinase inhibitors that counteract this activity are currently being tested in phase 1 clinical trials as a potential therapeutic target for Parkinson’s disease (reviewed in Atashrazm and Dzamko, 2016; Taymans and Greggio, 2016; Alessi and Sammler, 2018). The gene discussed is LRRK2; the disease is Parkinson disease.